<DOC>
	<DOCNO>NCT01687582</DOCNO>
	<brief_summary>The aim study evaluate 4 6 month effect GLP-1 analog treatment psoriatic skin lesion patient type 2 diabetes .</brief_summary>
	<brief_title>Effect GLP-1 Analogs Psoriasis Type 2 Diabetic Patients</brief_title>
	<detailed_description>The objective study analyse short medium-term efficacy clinical , immunological histopathological parameter GLP-1 receptor agonist moderate severe psoriasis plaque group patient type 2 diabetes .</detailed_description>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>Type 2 diabetic patient treat oral antihyperglycaemic agent and/or insulin present stable psoriasis plaque least one year , fail respond previous systemic and/or topical treatment . Type 1 diabetes Secondary diabetes Liver , renal pancreatic disease Previous treatment GLP1 agonist DPP4 inhibitor agent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>psoriasis</keyword>
	<keyword>exenatide</keyword>
	<keyword>liraglutide</keyword>
</DOC>